Abstract：Objective To conduct an epidemiological survey on the first clustering epidemic caused by an asymptomatic patient with novel coronavirus 2019 (COVID-19) infection in Jiaozuo city so as to effectively prevent and control the epidemic. Methods According to Protocol on Diagnosis and Treatment of COVID-19 (Trial Edition 4) and Protocol on Prevention and Control of COVID-19 (Edition 3), the real-time reverse transcription polymerase chain reaction (RT-PCR) assay was performed to detect the nucleic acid of SARS-CoV-2 from the sputum specimens or throat swabs of the case, and then the disease was categorized based on epidemiological history and clinical manifestations. A field investigation was conducted to find the clear route of transmission, track down the close contacts of the case, and implement the relevant prevention and control measures. Results The first case W in this aggregation epidemic had no definite epidemiological history. Z, the son of the case W, who had close contacts with the confirmed case S in a neighboring city 16 days ago, was confirmed as an asymptomatic COVID-19 infection patient based on the result of nucleic acid test, epidemiological history and clinical manifestations. There was an epidemiological association between W and Z; and hence, it was a family aggregation epidemic. Conclusions Asymptomatic COVID-19 infection patients can cause family aggregation epidemics through close contact transmission. It is necessary to enhance propaganda and education about COVID-19 prevention and control knowledge in families and management of the key groups so as to avoid the occurrence and spread of family aggregation epidemic.
[1] Guan WJ, Ni ZY, Hu Y, et al.Clinical characteristics of 2019 novel coronavirus infection in China[J].N Engl J Med, 2020,382(18):1708-1720. [2] Chan J, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J].Lancet, 2020, 395(10223):514-523. [3] 国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第四版)[Z].2020-01-27. [4] 国家卫生健康委员会.新型冠状病毒肺炎防控方案(第三版)[Z].2020-01-28. [5] 国家卫生健康委员会.新型冠状病毒肺炎防控方案(第四版)[Z].2020-02-07. [6] 中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志,2020,41(2):145-151. [7] 林君芬,吴梦娜,吴昊澄,等.浙江省新型冠状病毒肺炎病例流行特征分析[J].预防医学,2020,32(3):217-221,225. [8] 赵善露,高立冬,罗垲炜,等.湖南省新型冠状病毒肺炎聚集性疫情流行特征分析[J].实用预防医学,2020,27(5):517-520. [9] 田怀玉.2019-nCoV:来自冠状病毒的新挑战[J].中华预防医学杂志, 2020, 54(3): 233-236.
2020, Vol. 27 
